Premium
Qualitative Change in Migraine Prevention?
Author(s) -
Cady Roger,
Lipton Richard B.
Publication year - 2018
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/head.13354
Subject(s) - migraine , calcitonin gene related peptide , medicine , calcitonin , qualitative analysis , qualitative research , neuropeptide , receptor , social science , sociology
A new generation of drugs that target calcitonin gene‐related peptide (CGRP) pathways offers a unique opportunity to explore the relationship between responder rates (RRs) and improvement in patient outcomes. The authors hypothesize a “tipping point” exists for patients with a ≥75% migraine response. They propose higher RRs reported in trials with CGRP inhibitory antibodies deliver not only a quantitative change in monthly headache days, but also a qualitative change in function, for a clinically meaningful subpopulation of patients.